Sarcopenia defined by AWGS 2025 criteria was present in 59.3% of older Japanese adults with heart failure and was associated with a 2.36-fold increased risk of all-cause mortality (HR 2.361, 95% CI 1.203–4.637, p=0.013) compared to non-sarcopenic patients.
Cohort (n=253)
No
Does sarcopenia diagnosed by the AWGS 2025 criteria increase the risk of all-cause and cardiovascular mortality in older adults with heart failure?
Sarcopenia, as defined by the AWGS 2025 criteria, is highly prevalent in older Japanese adults with heart failure and is significantly associated with an increased risk of all-cause and cardiovascular mortality.
Effect estimate: HR 2.361 (95% CI 1.203–4.637)
Absolute Event Rate: 34.7% vs 18.4%
p-value: p=0.013
Older patients with HF have a high rate of sarcopenia, and sarcopenia, as defined by the AWGS 2025 criteria, is associated with an increased mortality risk.
Hashimoto et al. (Mon,) conducted a cohort in Heart failure (n=253). Sarcopenia diagnosed by Asian Working Group for Sarcopenia 2025 (AWGS 2025) criteria vs. Non-sarcopenia by AWGS 2025 criteria was evaluated on All-cause mortality (HR 2.361, 95% CI 1.203–4.637, p=0.013). Sarcopenia defined by AWGS 2025 criteria was present in 59.3% of older Japanese adults with heart failure and was associated with a 2.36-fold increased risk of all-cause mortality (HR 2.361, 95% CI 1.203–4.637, p=0.013) compared to non-sarcopenic patients.